HealthcareServices

Viral Vectors And Plasmid DNA Manufacturing Market Outlook 2026–2030: Key Business Drivers and Trends

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the viral vectors and plasmid dna manufacturing market from 2026–2035 with trusted insights from The Business Research Company

How much is the Viral Vectors And Plasmid DNA Manufacturing Market valued at in 2026, and what valuation is forecast for 2030?

The size of the viral vectors and plasmid dna manufacturing market has experienced substantial growth in recent years. This market is forecasted to increase from $7.11 billion in 2025 to $8.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. Historically, this expansion can be linked to factors such as the rise in gene therapy research programs, the broadening of vaccine development initiatives, increased funding for academic and clinical research, the early stages of cell therapy commercialization, and progress in molecular biology techniques.

The viral vectors and plasmid dna manufacturing market size is poised for significant expansion in the next few years, with projections indicating it will reach $20.36 billion by 2030, growing at a compound annual growth rate (CAGR) of 23.4%. This growth during the forecast period is propelled by factors such as increasing approvals of gene and cell therapies, a rising need for commercial-scale manufacturing, the expansion of CMO partnerships, a heightened focus on treatments for rare diseases, and continuous innovation in vector design and production efficiency. Noteworthy trends expected in this period include the increasing deployment of scalable viral vector manufacturing platforms, a rise in the adoption of single-use bioprocessing systems, a growing demand for high-purity plasmid dna, the expansion of contract manufacturing capacity, and an enhanced focus on regulatory-compliant production.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20690&type=smp

What Drivers Are Influencing The Growth Of The Viral Vectors And Plasmid DNA Manufacturing Market?

A growing number of gene therapies is projected to fuel the expansion of the viral vectors and plasmid DNA manufacturing market in the coming period. Gene therapy involves the introduction, removal, or alteration of genetic material within a person’s cells to manage or prevent illnesses. Advances in gene therapy are vital, stemming from increased investments in biotechnology research and development, alongside a deeper understanding of the genetic and cellular mechanisms that underpin various diseases. Viral vectors and plasmid DNA manufacturing are instrumental in delivering therapeutic genes into patients’ cells, enabling the treatment of genetic conditions at a molecular level. For instance, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the count of gene therapies in Phase III clinical trials saw a 10% increase in Q3 2023, representing the first quarterly rise observed since Q3 2022. Consequently, the rising volume of gene therapies is a primary driver for the viral vectors and plasmid DNA manufacturing market.

What Segments Are Included Within The Viral Vectors And Plasmid DNA Manufacturing Market?

The viral vectors and plasmid dna manufacturing market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Viral Vector, Non-Viral Vector

2) By Scale Of Operation: Preclinical, Clinical, Commercial

3) By Therapeutic Area: Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders, Other Disorders

4) By Application Area: Gene Therapies, Cell Therapies, Vaccines

5) By Type Of Manufacturer: In-house Manufacturers, Contract Manufacturing Organizations

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA, Circular Plasmid DNA, High-Copy Plasmid DNA, Low-Copy Plasmid DNA

2) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors (AAV), Retroviral Vectors

3) By Non-Viral Vector: Liposome-Based Vectors, Polymer-Based Vectors, Nanoparticle-Based Vectors, Electroporation-Based Vectors

Which Trends Are Expected To Influence The Viral Vectors And Plasmid DNA Manufacturing Market In The Upcoming Years?

Companies operating within the viral vectors and plasmid DNA manufacturing market are prioritizing strategic partnerships to broaden their production capabilities, strengthen technological expertise, and accelerate the global development and commercialization of gene therapies. These collaborations facilitate the sharing of resources and infrastructure among companies, thereby augmenting overall production capacity to fulfill the rising demand for gene therapies. For example, in June 2024, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, along with Captain T Cell, a spinoff from the esteemed Max Delbrück Center in Berlin, Germany, forged an agreement for a plasmid DNA and retrovirus vector production program. This partnership grants Captain T Cell access to established contract development and manufacturing (CDMO) capabilities and advisory services. Additionally, it aims to expedite the progression from preclinical research to clinical trials for a novel TCR-T cell therapy designed to target solid tumors.

Who Are The Major Companies Operating In The Viral Vectors And Plasmid DNA Manufacturing Market?

Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-manufacturing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Viral Vectors And Plasmid DNA Manufacturing Market?

North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid dna manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Viral Vectors And Plasmid DNA Manufacturing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20690&type=smp

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Manufacturing Market 2026, By The Business Research Company

Explosive Ordnance Disposal Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/explosive-ordnance-disposal-equipment-global-market-report

Bacterial And Plasmid Vector Market Report 2026

https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report

Prenatal Dna Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795